Navigation Links
Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics

FREISING-WEIHENSTEPHAN, Germany, September 5 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins(R) in ophthalmologic disease.

The studies reported by Pieris relate to PRS-055, an Anticalin(R) specific for VEGF. VEGF is a key factor in the regulation of neovascular permeability and is implicated in debilitating eye diseases such as age-related macular degeneration (AMD), proliferative diabetic retinopathy and retinopathy of prematurity. Intravitreal injection of PRS-055 has been shown to inhibit VEGF-induced breakdown of the blood-retinal barrier in a rabbit in vivo model. The antagonistic effect of PRS-055 has been shown to be of equivalent potency to that of the approved ophthalmology product Lucentis(R) (ranibizumab; Genentech / Novartis).

"These exciting results have demonstrated that Anticalins(R) are viable candidates as potent biotherapeutics for diseases of the eye" said Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris. "Based on the success of the PRS-055 program to date, we are now selecting technologies for depot and/or non-invasive drug delivery that will exploit the favorable size and excellent stability characteristics of Anticalins(R)."

The preclinical data on PRS-055 will be presented on September 8th, 2007, at the IV. International Symposium of the German Ophthalmological Society (DOG) in Baden-Baden, Germany.

Further information is available at

Anticalin(R) is registered trademark of Pieris AG.

For further information, please contact:

Pieris AG

Phone +49-(0)-8161-1411-400

Dr Andreas Hohlbaum,

Director of Science and Preclinical Research

Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Stem cell bank announcement validates quality of Wisconsin research
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family Foundation and ... Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. Established in ... by the New York Academy of Sciences to honor the excellence of outstanding ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of ... trends in analytical testing are being attributed to new regulatory requirements for all ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):